NZ594669A - Oral composition of Vorinostat - Google Patents

Oral composition of Vorinostat

Info

Publication number
NZ594669A
NZ594669A NZ594669A NZ59466906A NZ594669A NZ 594669 A NZ594669 A NZ 594669A NZ 594669 A NZ594669 A NZ 594669A NZ 59466906 A NZ59466906 A NZ 59466906A NZ 594669 A NZ594669 A NZ 594669A
Authority
NZ
New Zealand
Prior art keywords
dissolved
minutes
active ingredient
microns
pharmaceutically acceptable
Prior art date
Application number
NZ594669A
Other languages
English (en)
Inventor
Jeannie Chow Wong
Aaron S Cote
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ594669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NZ594669A publication Critical patent/NZ594669A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ594669A 2005-05-20 2006-05-16 Oral composition of Vorinostat NZ594669A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23
NZ553204A NZ553204A (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Publications (1)

Publication Number Publication Date
NZ594669A true NZ594669A (en) 2013-02-22

Family

ID=37452585

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ594669A NZ594669A (en) 2005-05-20 2006-05-16 Oral composition of Vorinostat
NZ553204A NZ553204A (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ553204A NZ553204A (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP2292221A3 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100993135B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ594669A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI365068B (OSRAM)
WO (2) WO2006127319A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
NZ592686A (en) 2008-10-15 2012-12-21 Generics Uk Ltd Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
CN102282126A (zh) * 2008-11-26 2011-12-14 基因里克斯(英国)有限公司 多晶型物
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
KR20010080142A (ko) 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002102323A2 (en) 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2003219803B8 (en) 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1567142A4 (en) 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
CN1839121A (zh) 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
CA2535806C (en) * 2003-08-26 2009-02-17 Aton Pharma, Inc. The use of hdac inhibitors for the treatment of cancer
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
EP1942884A4 (en) 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
CN101300015A (zh) 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
US20070197473A1 (en) 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer

Also Published As

Publication number Publication date
WO2006127321A2 (en) 2006-11-30
EP2292221A3 (en) 2011-08-10
US20080132575A1 (en) 2008-06-05
IL181070A0 (en) 2007-07-04
DOP2006000113A (es) 2006-10-31
AU2009201652B2 (en) 2011-10-06
KR20080113135A (ko) 2008-12-26
CA2580367A1 (en) 2006-11-30
US8288440B2 (en) 2012-10-16
ECSP077263A (OSRAM) 2007-04-26
MX2007002047A (es) 2007-04-12
PE20061390A1 (es) 2007-01-15
AU2010201359A1 (en) 2010-04-29
AR055953A1 (es) 2007-09-12
JP5264174B2 (ja) 2013-08-14
WO2006127319A2 (en) 2006-11-30
JP2011251985A (ja) 2011-12-15
MY144613A (en) 2011-10-04
EP1853245A2 (en) 2007-11-14
US8450372B2 (en) 2013-05-28
AU2006249440B2 (en) 2009-03-12
AU2009201652A1 (en) 2009-05-21
AU2009201650A1 (en) 2009-05-21
NI200700031A (es) 2008-03-03
EP2292221A2 (en) 2011-03-09
AU2006249440A1 (en) 2006-11-30
KR100993135B1 (ko) 2010-11-10
TWI365068B (en) 2012-06-01
CR8912A (es) 2008-02-21
US20100113829A1 (en) 2010-05-06
US8093295B2 (en) 2012-01-10
US20100112046A1 (en) 2010-05-06
TW200727892A (en) 2007-08-01
MA28804B1 (fr) 2007-08-01
KR20070062505A (ko) 2007-06-15
KR100884500B1 (ko) 2009-02-20
AU2009201650B2 (en) 2011-09-15
NZ553204A (en) 2011-09-30
TW201034660A (en) 2010-10-01
CA2580367C (en) 2012-08-21
AU2006249440C1 (en) 2009-08-13
JP2008519081A (ja) 2008-06-05
WO2006127319A3 (en) 2007-03-29
TWI415603B (zh) 2013-11-21
US20100119596A1 (en) 2010-05-13
BRPI0605893A (pt) 2007-12-18
WO2006127321A3 (en) 2007-03-22
JP5308486B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
US10786507B2 (en) Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
MX2007005377A (es) Particulas de ramiprilo estabilizadas, individualmente recubiertas, composiciones y metodos.
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
HK1039897A1 (zh) 选择性醛甾酮受体拮抗剂「eplerenone」毫微粒子合成物
JP2006528221A5 (OSRAM)
SK282506B6 (sk) Tableta obsahujúca paracetamol a domperidon
MY160652A (en) Pharmaceutical composition for oral administration
KR20150036553A (ko) 알칼리화제를 함유하지 않는 라퀴니모드 제형
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
CA2469019A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
NZ594669A (en) Oral composition of Vorinostat
KR20010024187A (ko) 호흡기 질환의 치료를 위한 조성물 및 방법
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
GEP20053610B (en) Pediatric Formulation Of Gatifloxacin
JP2017036226A (ja) 生薬末含有錠剤
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
ITMI20080798A1 (it) Composizione a rilascio modificato a base di doxofillina
AU2020204558A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
TW200505504A (en) Saquinavir mesylate oral dosage form
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени
CA2653017A1 (en) Robust sustained release formulations of oxymorphone and methods of use thereof
WO2005079753A3 (en) Extended release pharmaceutical compositions of divalproex sodium
JP6838632B2 (ja) 固形製剤

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): MERCK SHARP AND DOHME CORP.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 16 MAY 2016 BY AJ PARK

Effective date: 20130828

LAPS Patent lapsed